Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s share price rose 1.9% during mid-day trading on Thursday . The company traded as high as $3.27 and last traded at $3.24. Approximately 15,739 shares traded hands during trading, an increase of 86% from the average daily volume of 8,450 shares. The stock had previously closed at $3.18.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on EPRX. Rodman & Renshaw began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, November 14th. They issued a "buy" rating and a $9.00 target price on the stock. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, November 14th.
View Our Latest Research Report on EPRX
Eupraxia Pharmaceuticals Stock Up 1.2 %
The firm has a market cap of $116.83 million and a PE ratio of -4.56. The company's 50 day moving average price is $3.12 and its two-hundred day moving average price is $2.88.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in EPRX. Raymond James Financial Inc. purchased a new position in Eupraxia Pharmaceuticals in the 4th quarter worth about $37,000. Millennium Management LLC bought a new position in Eupraxia Pharmaceuticals during the 4th quarter worth about $31,000. Finally, Bank of Montreal Can grew its holdings in Eupraxia Pharmaceuticals by 15.2% during the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock worth $178,000 after acquiring an additional 7,500 shares in the last quarter.
Eupraxia Pharmaceuticals Company Profile
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Further Reading
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
